Ludimila Cavalcante - JoVE Visualize

Showing results (31-40 of 32) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 32 results.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced MalignanciesBenedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.

Cancers|October 28, 2023

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.

Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 32 results.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced MalignanciesBenedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.

Cancers|October 28, 2023

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.

Pageof 4